[go: up one dir, main page]

MX2023013207A - Anticuerpo agonista anti-pd-1 humano para tratar o prevenir enfermedades inflamatorias, y composicion farmaceutica que contiene el mismo. - Google Patents

Anticuerpo agonista anti-pd-1 humano para tratar o prevenir enfermedades inflamatorias, y composicion farmaceutica que contiene el mismo.

Info

Publication number
MX2023013207A
MX2023013207A MX2023013207A MX2023013207A MX2023013207A MX 2023013207 A MX2023013207 A MX 2023013207A MX 2023013207 A MX2023013207 A MX 2023013207A MX 2023013207 A MX2023013207 A MX 2023013207A MX 2023013207 A MX2023013207 A MX 2023013207A
Authority
MX
Mexico
Prior art keywords
human
agonist antibody
inflammatory diseases
treating
pharmaceutical composition
Prior art date
Application number
MX2023013207A
Other languages
English (en)
Inventor
Kensuke Suzuki
Tasuku Honjo
Satoshi Nagata
Takayoshi Fukushima
Akio Ohta
Masaki Tajima
Haruhiko KAMADA
Yosuke Tokumaru
Original Assignee
Foundation For Biomedical Res And Innovation At Kobe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foundation For Biomedical Res And Innovation At Kobe filed Critical Foundation For Biomedical Res And Innovation At Kobe
Publication of MX2023013207A publication Critical patent/MX2023013207A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a la búsqueda de las condiciones necesarias para que un anticuerpo contra PD-1 humano posea una actividad agonista, al establecimiento de un anticuerpo agonista optimizado con base en dichas condiciones necesarias y a la aplicación de dicho anticuerpo agonista como fármaco para enfermedades inflamatorias humanas. Un anticuerpo agonista contra PD-1 humano o un fragmento funcional del mismo de acuerdo con la presente invención se caracteriza porque el anticuerpo o el fragmento funcional del mismo se une al dominio #7 de PD-1 humano representado por SEQ ID NO: 9.
MX2023013207A 2021-05-13 2022-05-12 Anticuerpo agonista anti-pd-1 humano para tratar o prevenir enfermedades inflamatorias, y composicion farmaceutica que contiene el mismo. MX2023013207A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021081913 2021-05-13
JP2021086534 2021-05-21
PCT/JP2022/020011 WO2022239820A1 (ja) 2021-05-13 2022-05-12 炎症性疾患を治療又は予防するための抗ヒトｐｄ－１アゴニスト抗体及びこれを含有する医薬組成物

Publications (1)

Publication Number Publication Date
MX2023013207A true MX2023013207A (es) 2023-11-15

Family

ID=84029692

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013207A MX2023013207A (es) 2021-05-13 2022-05-12 Anticuerpo agonista anti-pd-1 humano para tratar o prevenir enfermedades inflamatorias, y composicion farmaceutica que contiene el mismo.

Country Status (13)

Country Link
US (1) US20240317859A1 (es)
EP (1) EP4339289A4 (es)
JP (1) JPWO2022239820A1 (es)
KR (1) KR20240007203A (es)
AR (1) AR125887A1 (es)
AU (1) AU2022272835A1 (es)
BR (1) BR112023023400A2 (es)
CA (1) CA3217199A1 (es)
IL (1) IL307887A (es)
MX (1) MX2023013207A (es)
TW (1) TW202311290A (es)
UY (1) UY39768A (es)
WO (1) WO2022239820A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4159235A4 (en) * 2020-05-25 2024-07-10 Foundation for Biomedical Research and Innovation at Kobe PHARMACEUTICAL COMPOSITION CONTAINING PD-1 AGONIST FOR TREATING OR PREVENTING TH2-MEDIATED DISEASE
AU2023367781A1 (en) 2022-10-25 2025-06-05 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
CN117024595B (zh) * 2023-10-08 2024-01-26 江西乐成欣生生物技术研究有限责任公司 抗人st2的单克隆抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
CA2736829C (en) * 2008-09-12 2018-02-27 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
US9701749B2 (en) * 2011-08-11 2017-07-11 Ono Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising PD-1 agonist
WO2017058859A1 (en) 2015-09-29 2017-04-06 Celgene Corporation Pd-1 binding proteins and methods of use thereof
CR20190550A (es) 2017-06-05 2020-04-05 Janssen Biotech Inc Anticuerpos que se unen específicamente a pd-1 y métodos de uso
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
AR114127A1 (es) * 2018-03-02 2020-07-22 Lilly Co Eli Anticuerpos agonistas contra pd-1 y usos de estos
CA3100253A1 (en) 2018-05-14 2019-11-21 Immunocore Limited Bifunctional binding polypeptides
WO2020247648A2 (en) 2019-06-05 2020-12-10 Anaptysbio, Inc. Pd-1 agonist and method of using same
JP7185614B2 (ja) 2019-11-18 2022-12-07 株式会社エクスモーション 情報処理装置、及び情報処理プログラム
JP7310572B2 (ja) 2019-11-29 2023-07-19 日本電気株式会社 計数装置、制御方法、及びプログラム
EP4159235A4 (en) * 2020-05-25 2024-07-10 Foundation for Biomedical Research and Innovation at Kobe PHARMACEUTICAL COMPOSITION CONTAINING PD-1 AGONIST FOR TREATING OR PREVENTING TH2-MEDIATED DISEASE

Also Published As

Publication number Publication date
JPWO2022239820A1 (es) 2022-11-17
AU2022272835A1 (en) 2023-11-02
WO2022239820A1 (ja) 2022-11-17
TW202311290A (zh) 2023-03-16
AR125887A1 (es) 2023-08-23
IL307887A (en) 2023-12-01
AU2022272835A9 (en) 2023-11-16
UY39768A (es) 2022-11-30
US20240317859A1 (en) 2024-09-26
EP4339289A4 (en) 2025-10-08
BR112023023400A2 (pt) 2024-01-23
EP4339289A1 (en) 2024-03-20
CA3217199A1 (en) 2022-11-17
KR20240007203A (ko) 2024-01-16

Similar Documents

Publication Publication Date Title
MX2023013207A (es) Anticuerpo agonista anti-pd-1 humano para tratar o prevenir enfermedades inflamatorias, y composicion farmaceutica que contiene el mismo.
BR112023015527A2 (pt) Inibidores de cdk e métodos de uso destes
MX2023001538A (es) Composiciones y metodos para inhibir la expresion de lpa.
CO2023002206A2 (es) Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas trem2
CL2024001964A1 (es) Compuestos para la inhibición de nlrp3 y usos de estos
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
BRPI0211953B8 (pt) anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro
BR112021022497A2 (pt) Composto, composição farmacêutica, uso da composição farmacêutica, e, métodos para prevenir ou tratar obesidade, diabetes, inflamação e disfunção erétil
ECSP19001438A (es) Anticuerpos anti_ige
CR20220536A (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune
MX2023004300A (es) Direccionamiento in vivo de células t para terapia con ácido ribonucleico mensajero (arnm).
PE20081264A1 (es) Anticuerpos agonistas anti-notch3
CO2025015814A2 (es) Inhibidores de kras de 2-azabiciclo [2.2.1] heptano
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
EA201390874A1 (ru) Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение
PA8601001A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
MX2024003107A (es) Agonistas de ahr.
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
SA522441554B1 (ar) Ripk1 مركبات أيزوكسازوليدين كمثبطات واستخدامها
JP1788543S (ja) 眼用インジェクター
CL2021003455A1 (es) Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
BR112023017367A2 (pt) Composições e métodos para inibição de ceto-hexoquinase (khk)
BR112015023086A2 (pt) anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-cd25 ou fragmento ligante anti cd25, para prevenção de rejeição de órgãos transplantados e para tratamento de uma doença.
MX2022010693A (es) Compuestos, composiciones y metodos para inhibidores de la proteina quinasa que interactua con el receptor i para el tratamiento de enfermedades.